Sanofi SA
SNY48.470USD
+0.110+0.23%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
117.99BCap. mercado
11.73P/E TTM
Más Datos de Sanofi SA Compañía
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Información de Sanofi SA
Símbolo de cotizaciónSNY
Nombre de la empresaSanofi SA
Fecha de salida a bolsaJul 01, 2002
Director ejecutivoHudson (Paul)
Número de empleados84587
Tipo de seguridadDepository Receipt
Fin del año fiscalJul 01
Dirección46 Avenue de la Grande Armee
CiudadPARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75017
Teléfono33153774000
Sitio Webhttps://www.sanofi.com/
Símbolo de cotizaciónSNY
Fecha de salida a bolsaJul 01, 2002
Director ejecutivoHudson (Paul)
Ejecutivos de Sanofi SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
5.53B
48.81%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
4.21B
37.18%
Europe
2.38B
21.02%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Dodge & Cox
2.83%
Fisher Investments
0.52%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.26%
T. Rowe Price Associates, Inc.
0.24%
Otro
95.85%
Accionistas
Accionistas
Proporción
Dodge & Cox
2.83%
Fisher Investments
0.52%
Barrow Hanley Global Investors
0.29%
Managed Account Advisors LLC
0.26%
T. Rowe Price Associates, Inc.
0.24%
Otro
95.85%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
4.90%
Investment Advisor
3.76%
Research Firm
0.80%
Hedge Fund
0.32%
Bank and Trust
0.07%
Family Office
0.02%
Pension Fund
0.02%
Otro
90.11%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1269
251.34M
10.32%
-27.29M
2025Q2
1261
264.33M
10.86%
-14.23M
2025Q1
1286
268.29M
10.62%
-13.21M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Dodge & Cox
71.72M
2.95%
-1.47M
-2.01%
Jun 30, 2025
Fisher Investments
13.14M
0.54%
-430.96K
-3.18%
Jun 30, 2025
Barrow Hanley Global Investors
7.28M
0.3%
-68.91K
-0.94%
Jun 30, 2025
Managed Account Advisors LLC
7.48M
0.31%
-87.85K
-1.16%
Jun 30, 2025
T. Rowe Price Associates, Inc.
5.52M
0.23%
-5.51M
-49.93%
Jun 30, 2025
Invesco Advisers, Inc.
8.56M
0.35%
-2.81M
-24.69%
Jun 30, 2025
Wellington Management Company, LLP
4.33M
0.18%
-96.41K
-2.18%
Jun 30, 2025
Putnam Investment Management, L.L.C.
4.13M
0.17%
+408.18K
+10.97%
Jun 30, 2025
Boston Partners
3.99M
0.16%
-100.31K
-2.45%
Jun 30, 2025
Mondrian Investment Partners Ltd.
3.44M
0.14%
-10.43K
-0.30%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Nombre
Proporción
VanEck Pharmaceutical ETF
10.04%
Invesco International Dividend Achievers ETF
3.05%
Altrius Global Dividend ETF
2.41%
Brandes US Value ETF
2.14%
Putnam Focused Large Cap Value ETF
1.9%
American Century Focused Large Cap Value ETF
1.42%
ProShares Ultra Nasdaq Biotechnology
1.33%
Invesco Nasdaq Biotechnology ETF
1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
0.97%
Invesco NASDAQ Next Gen 100 ETF
0.74%
Ver más
VanEck Pharmaceutical ETF
Proporción10.04%
Invesco International Dividend Achievers ETF
Proporción3.05%
Altrius Global Dividend ETF
Proporción2.41%
Brandes US Value ETF
Proporción2.14%
Putnam Focused Large Cap Value ETF
Proporción1.9%
American Century Focused Large Cap Value ETF
Proporción1.42%
ProShares Ultra Nasdaq Biotechnology
Proporción1.33%
Invesco Nasdaq Biotechnology ETF
Proporción1.32%
Invesco ESG NASDAQ Next Gen 100 ETF
Proporción0.97%
Invesco NASDAQ Next Gen 100 ETF
Proporción0.74%
Dividendos
Un total de
23.51B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Apr 15, 2025
SNY.NB Final Cash Dividend of gross USD 2.195331 paid on Jun 12, 2025 going ex on May 09, 2025
May 09, 2025
Jun 12, 2025
May 09, 2025
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Sanofi SA?
Los cinco principales accionistas de Sanofi SA son:
Dodge & Cox posee 71.72M acciones, lo que representa el 2.95% del total de acciones.
Fisher Investments posee 13.14M acciones, lo que representa el 0.54% del total de acciones.
Barrow Hanley Global Investors posee 7.28M acciones, lo que representa el 0.30% del total de acciones.
Managed Account Advisors LLC posee 7.48M acciones, lo que representa el 0.31% del total de acciones.
T. Rowe Price Associates, Inc. posee 5.52M acciones, lo que representa el 0.23% del total de acciones.
Dodge & Cox posee 71.72M acciones, lo que representa el 2.95% del total de acciones.
Fisher Investments posee 13.14M acciones, lo que representa el 0.54% del total de acciones.
Barrow Hanley Global Investors posee 7.28M acciones, lo que representa el 0.30% del total de acciones.
Managed Account Advisors LLC posee 7.48M acciones, lo que representa el 0.31% del total de acciones.
T. Rowe Price Associates, Inc. posee 5.52M acciones, lo que representa el 0.23% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Sanofi SA?
Los tres principales tipos de accionista de Sanofi SA son:
Dodge & Cox
Fisher Investments
Barrow Hanley Global Investors
Dodge & Cox
Fisher Investments
Barrow Hanley Global Investors
¿Cuántas instituciones poseen acciones de Sanofi SA (SNY)?
A fecha de 2025Q3, 1269 instituciones poseen acciones de Sanofi SA, con un valor de mercado combinado de aproximadamente 251.34M, lo que representa el 10.32% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -0.53%.
¿Cuál es la mayor fuente de ganancias de Sanofi SA?
El FY2025Q2, el segmento empresarial -- generó la ganancia más alta para Sanofi SA, ascendiendo a -- y representando el --% de la ganancia total.
